Filtered By:
Source: Clinical Cancer Research
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4-CHOP-DR5 Axis in Human Esophageal Cancer Cells.
CONCLUSION: Our findings highlight a critical role of ATF4-CHOP-DR5 axis-mediated extrinsic apoptosis in neddylation-targeted cancer therapy and support the clinical investigation of neddylation inhibitors (e.g. MLN4924) for the treatment of ESCC, a currently treatment-resistant disease with neddylation hyperactivation.
PMID: 26983464 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 16, 2016 Category: Cancer & Oncology Authors: Chen P, Hu T, Liang Y, Li P, Chen X, Zhang J, Ma Y, Hao Q, Wang J, Zhang P, Zhang Y, Zhao H, Yang S, Yu J, Jeong LS, Qi H, Yang M, Hoffman RM, Dong Z, Jia L Tags: Clin Cancer Res Source Type: research
Trop-2 induces tumor growth through Akt and determines sensitivity to Akt inhibitors.
CONCLUSION: Our findings indicate that the expression of Trop-2 is a stringent predictor of tumor response to Akt inhibitors. They also support the identification of target-activatory pathways, as efficient predictors of response in precision cancer therapy.
PMID: 27022065 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 27, 2016 Category: Cancer & Oncology Authors: Guerra E, Trerotola M, Tripaldi R, Aloisi AL, Simeone P, Sacchetti A, Relli V, D' Amore A, La Sorda R, Lattanzio R, Piantelli M, Alberti S Tags: Clin Cancer Res Source Type: research
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy.
CONCLUSIONS: VAC14 should be prioritized for further validation of its potential role as a predictor of docetaxel-induced neuropathy and biomarker for treatment individualization.
PMID: 27143689 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 2, 2016 Category: Cancer & Oncology Authors: Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel JN, Halabi S, Furukawa Y, Wheeler HE, Sibley A, Lassiter C, Weisman LS, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz D, Friedman PN, Mahoney JF, Carducci MA, Ke Tags: Clin Cancer Res Source Type: research
MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
CONCLUSIONS: The combination of MAPK pathway inhibitors with an antibody-drug-conjugate targeting GPNMB is an effective therapeutic option for patients with melanoma.
PMID: 27515299 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 10, 2016 Category: Cancer & Oncology Authors: Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong LN, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM Tags: Clin Cancer Res Source Type: research
Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer.
CONCLUSION: XPO5 acts like an oncogene in CRC by regulating the expression of miRNAs and may be a potential therapeutic target in CRC.
PMID: 27553833 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 22, 2016 Category: Cancer & Oncology Authors: Shigeyasu K, Okugawa Y, Toden S, Boland CR, Goel A Tags: Clin Cancer Res Source Type: research
Overexpression of functional SLC6A3 in clear cell renal cell carcinoma.
CONCLUSIONS: We conclude that the dopamine transporter SLC6A3 constitute a novel biomarker that is highly specific for ccRCC. We further postulate that the protein can be exploited for diagnostic or therapeutic purposes for detection or treatment of ccRCC.
PMID: 27663598 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 22, 2016 Category: Cancer & Oncology Authors: Hansson J, Lindgren D, Nilsson H, Johansson E, Johansson M, Gustavsson L, Axelson H Tags: Clin Cancer Res Source Type: research
Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.
CONCLUSIONS: These findings suggest a specific dependency of CCNE1 amplified tumors for AKT activity, and point to a novel combination of dinaciclib and AKT inhibitors that may selectively target patients with CCNE1 amplified HGSC.
PMID: 27663592 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 22, 2016 Category: Cancer & Oncology Authors: Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD Tags: Clin Cancer Res Source Type: research
A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
CONCLUSIONS: ARN-3236 is the first orally available inhibitor of SIK2 to be evaluated against ovarian cancer in preclinical models and shows promise in inhibiting ovarian cancer growth and enhancing paclitaxel chemosensitivity.
PMID: 27678456 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 26, 2016 Category: Cancer & Oncology Authors: Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill J, Yerramreddy V, Alsaadid A, Ahmed AA, Yang H, Liu J, Mao W, Takemori H, Wang Y, Vankayalapati H, Lu Z, Bast RC Tags: Clin Cancer Res Source Type: research
Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer.
CONCLUSIONS: Our analysis revealed distinct transcriptional expression profiles of the Mediator complex across cancer entities indicating differential modes of transcriptional regulation. Moreover it identified CDK19 and CDK8 to be specifically overexpressed during PCa progression, highlighting their potential as novel therapeutic targets in advanced PCa.
PMID: 27678455 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 26, 2016 Category: Cancer & Oncology Authors: Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S Tags: Clin Cancer Res Source Type: research
Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
CONCLUSION: We developed a technically and biologically robust NanoString gene expression assay of MEK pathway output, compatible with the quantities of FFPET routinely available. The gene signatures identified a different patient population for MEK inhibitor treatment compared with KRAS mutation testing. The predictive power of the MEK signature should be studied further in clinical trials.
PMID: 27733477 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 11, 2016 Category: Cancer & Oncology Authors: Brant RG, Sharpe A, Liptrot T, Dry J, Harrington EA, Barrett JC, Whalley N, Womack C, Smith PD, Hodgson D Tags: Clin Cancer Res Source Type: research
Biased Expression of the FOXP3 Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
CONCLUSIONS: (i) Biased expression of the FOXP3Δ3 isoform in bladder cancer inversely correlates with overall survival, (ii) FOXP3Δ3 induces a unique gene program that mediates cancer differentiation, and (iii) FOXP3Δ3 may augment chemotherapy resistance. Clin Cancer Res; 22(21); 5349-61. ©2016 AACR.
PMID: 27189164 [PubMed - in process]
Source: Clinical Cancer Research - October 31, 2016 Category: Cancer & Oncology Authors: Zhang H, Prado K, Zhang KX, Peek EM, Lee J, Wang X, Huang J, Li G, Pellegrini M, Chin AI Tags: Clin Cancer Res Source Type: research
AMPK-ULK1-mediated autophagy confers resistance to BET inhibitor JQ1 in acute myeloid leukemia stem cells.
CONCLUSIONS: These findings revealed that prosurvival autophagy was one of the mechanisms involved in the resistance AML LSCs to JQ1. Targeting the AMPK/ULK1 pathway or inhibition of autophagy could be an effective therapeutic strategy for combating resistance to BET inhibitors in AML and other types of cancer.
PMID: 27864418 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 17, 2016 Category: Cancer & Oncology Authors: Jang JE, Eom JI, Jeung HK, Cheong JW, Lee JY, Kim JS, Min YH Tags: Clin Cancer Res Source Type: research
Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma.
CONCLUSIONS: We identified a new MPM molecular subgroup that shares common genetic and transcriptomic characteristics. Our results made it possible to highlight a greater sensitivity to an anticancer compound for this MPM subgroup and to identify a specific potential biomarker.
PMID: 28003305 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 20, 2016 Category: Cancer & Oncology Authors: Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, de Reyniès A, Le Pimpec Barthes F, Zucman-Rossi J, Jaurand MC, Jean D Tags: Clin Cancer Res Source Type: research
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
CONCLUSIONS: Overall, these data demonstrate that prexasertib is a specific inhibitor of CHK1 in neuroblastoma and leads to DNA damage and cell death in preclinical models of this devastating pediatric malignancy.
PMID: 28270495 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 6, 2017 Category: Cancer & Oncology Authors: Lowery CD, VanWye AB, Dowless M, Blosser W, Falcon BL, Stewart J, Stephens J, Beckmann RP, Bence Lin A, Stancato LF Tags: Clin Cancer Res Source Type: research
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
CONCLUSIONS: Our preclinical studies provide the framework for clinical evaluation of USP1 inhibitors, alone or in combination, as a potential novel MM therapy.
PMID: 28270494 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 6, 2017 Category: Cancer & Oncology Authors: Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC Tags: Clin Cancer Res Source Type: research
